Skip to content

A comparative study of the efficacy of an orthotopic neobladder (Urumqi bladder) and a classic W-type orthotopic neobladder

A comparative study of the efficacy of an orthotopic neobladder (Urumqi bladder) and a classic W-type orthotopic neobladder

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055444
Enrollment
Unknown
Registered
2022-01-10
Start date
2022-01-10
Completion date
Unknown
Last updated
2023-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder cancer

Interventions

Group 1:new orthotopic bladder
Group 2:classic W-shaped orthotopic neobladder

Sponsors

The First Affiliated Hospital of Xinjiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 76 Years

Inclusion criteria

Inclusion criteria: 1. The subjects participated voluntarily and signed the informed consent; 2. Male, aged >=18 years and <=76 years; 3. Pathologically diagnosed with bladder urothelial carcinoma, no distant metastasis, locally resectable muscle-invasive bladder cancer (T2N0M0); high-risk non-muscle-invasive bladder cancer, including: recurrent or multiple T1G3 (or high-grade) tumors; T1G3 (high-grade) tumors with CIS; tumors that do not respond to BCG therapy; extensive papillary lesions uncontrolled by TUR and intravesical instillation; 4. ECOG score 0-1 points; 5. The function of important organs such as heart, brain, liver and kidney is normal; 6. No obvious lesions in the intestine; 7. The urethra is intact and the external sphincter function is good; 8. No other contraindications to surgery.

Exclusion criteria

Exclusion criteria: 1. Bilateral upper urinary tract hydrops, ureteral dilatation; 2. Combined with urethral stricture, the dilation treatment is ineffective; 3. Combined with urethral tumor; 4. History of tumors in other parts within the past 2 years; 5. Those with serious mental illness who cannot cooperate with treatment; 6. Those who have a history of abdominal and pelvic radiotherapy in the past; 7. Intraoperative pelvic lymph nodes were positive; 8. Rapid pathologically positive urethral resection margin.

Design outcomes

Primary

MeasureTime frame
Total complication rate;The incidence of unilateral hydronephrosis;Bladder residual urine volume;

Secondary

MeasureTime frame
Incidence of bowel obstruction;Rehospitalization rate within three months;Reoperation intervention rate;

Countries

China

Contacts

Public ContactWang Wen'guang

The First Affiliated Hospital of Xinjiang Medical University

wwg0903@163.com+86 13659917670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026